On this page
What is Idiopathic Intracranial Hypertension (Pseudotumor Cerebri)?
Idiopathic intracranial hypertension (IIH) is a neurological condition in which the pressure inside the skull is abnormally elevated. Its effects on the brain can mimic those of a brain tumor. For this reason, it is also known as pseudotumor cerebri, which literally means “false brain tumor”. However, it is entirely unrelated to any form of cancer or tumor growth.
Breaking down the name helps clarify the nature of the condition:
- Hypertension: abnormally elevated pressure
- Intracranial: within the skull (a rigid bony structure that, unlike soft tissue, cannot expand to accommodate increased pressure)
- Idiopathic: no identifiable underlying cause is found
IIH occurs when cerebrospinal fluid (CSF), the clear fluid that surrounds and cushions the entire central nervous system, including both the brain and spinal cord, builds up in excessive amounts within the skull. This excess fluid exerts abnormal pressure on the brain and, critically, on the optic nerve, which is directly connected to the eyes and is particularly vulnerable to pressure-induced damage.
The most common symptoms of IIH include:
- Severe headache.
- Visual disturbances, which may present as:
- Loss of peripheral (side) visual field, and more rarely central vision.
- Blurred vision.
- Double vision (diplopia).
- Photophobia (abnormal sensitivity to light).
- Pulsatile tinnitus is a rhythmic ringing or whooshing sound that patients hear. This sound matches the heartbeat but does not exist in the external environment.
IIH predominantly affects women of childbearing age who are overweight or obese, though it can occur in individuals of any age or sex. The condition can become seriously debilitating, and if left untreated, it may lead to permanent vision loss. Timely diagnosis and treatment are therefore essential.
Causes
IIH typically affects women between 20 and 44 years of age; women account for approximately 90% of all cases, and elevated body weight is the single most significant risk factor. The condition is uncommon in children, where neither sex predominates and obesity is less strongly correlated with risk.
The space between the brain and the skull is filled with cerebrospinal fluid (CSF), a clear liquid produced by specialized structures within the brain (the choroid plexuses) and normally reabsorbed at a balanced rate. In IIH, an excess of CSF accumulates within the intracranial compartment, generating abnormally high pressure on the brain and optic nerves.
The precise mechanisms by which this occurs remain poorly understood. Current evidence suggests it may involve reduced CSF reabsorption, increased CSF production, or a combination of both, possibly mediated by hormonal, metabolic, or venous drainage abnormalities.
Note: This article focuses specifically on the idiopathic form of intracranial hypertension. For cases secondary to other identifiable conditions, please refer to the dedicated article on intracranial hypertension.
Risk Factors
According to the NHS, recognized risk factors for the development of IIH include:
- Overweight or obesity, the strongest and most consistently identified risk factor, shows a close association with new-onset IIH. Weight gain often triggers the condition, while weight loss frequently leads to remission.
- Hormonal disorders, including:
- Cushing’s syndrome.
- Hypoparathyroidism.
- Hypothyroidism (underactive thyroid).
- Hyperthyroidism (overactive thyroid).
- Certain medications, including:
- Antibiotics (particularly tetracyclines such as doxycycline and minocycline).
- Corticosteroids, especially when discontinued.
- Excess vitamin A or retinoids (including isotretinoin).
- Lithium.
- Oral contraceptive pills.
- Hematological conditions, including:
- Iron deficiency anemia.
- Excess red blood cells (polycythemia).
- Chronic kidney disease.
- Systemic lupus erythematosus (lupus).
Understanding and addressing modifiable risk factors, particularly obesity, is central to both prevention and management.
Symptoms
The clinical presentation of IIH is largely driven by elevated intracranial pressure and its effects on the brain and optic nerves. The most characteristic symptoms include:
Headache
The headache associated with IIH is often the most prominent and disabling symptom. It may be:
- Bilateral or frontal in location, or felt behind the eyes
- Daily or near-daily in frequency
- Worse in the morning, upon waking
- Aggravated by activities that transiently increase intracranial pressure, such as coughing or the Valsalva maneuver (as demonstrated in the literature)
The headache is frequently accompanied by nausea and vomiting, light sensitivity (photophobia), and pain radiating to the neck and back.
Transient Visual Loss
Episodes of sudden, brief visual loss may affect one or both eyes. These episodes are typically transient, lasting only a few seconds, and are thought to be related to papilledema (swelling of the optic disc), which causes temporary interruptions in blood flow to the optic nerve.
Diplopia (Double Vision)
Double vision results from paralysis of the sixth cranial nerve (abducens nerve), affecting both eyes. This is a common and sometimes the presenting sign of elevated intracranial pressure.
Pulsatile Tinnitus
A rhythmic, pulse-synchronous sound, often described as a whooshing, rushing, or heartbeat-like noise heard in one or both ears, is a hallmark symptom of IIH. This sound may also be referred to as pulsatile tinnitus. It is caused by turbulent blood flow through the venous sinuses adjacent to the auditory structures and is perceived only by the patient (subjective tinnitus).
Photopsia
Some patients report sudden flashes of light (photopsia), which may be associated with optic nerve involvement or retinal changes secondary to elevated pressure.
Persistent Visual Loss
Permanent visual field loss occurs in up to 32% of cases, with the majority of those affected being individuals who did not receive timely or adequate treatment. This represents the most serious long-term consequence of unmanaged IIH.
Complications
The prognosis of IIH is highly variable and depends on several key factors:
- Rapidity of symptom onset: a more sudden or aggressive onset typically requires more intensive treatment
- Degree of visual loss at presentation: significant vision loss at the time of diagnosis is a major predictor of permanent visual impairment
- Severity of papilledema at presentation: more advanced optic disc swelling correlates with higher risk of optic nerve damage
Even with prompt and appropriate treatment, IIH can cause symptoms that persist for months or years. It is not uncommon for the condition to follow a chronic, fluctuating course.
The most serious complication is permanent blindness, resulting from sustained compression and ischemic damage to the optic nerve. Additional complications may arise from the treatments themselves, including adverse effects of medications, risks associated with surgical interventions, and complications related to lumbar puncture (spinal tap).
Diagnosis
Diagnosis of IIH is inherently multidisciplinary, requiring input from both neurology and ophthalmology, as the hallmark findings span both specialties.
Key clinical findings at presentation include:
- Papilledema is swelling of the optic disc, detected on fundoscopic examination. It occurs due to elevated intracranial pressure, which is transmitted along the optic nerve sheath.
- Visual field defects, which typically affect the peripheral visual fields.
- Sixth cranial nerve palsy, which causes horizontal diplopia.
Diagnostic Investigations
1. Neuroimaging
- MRI (Magnetic Resonance Imaging) is the gold standard and the preferred first-line imaging modality. It is used primarily to exclude secondary causes of raised intracranial pressure (such as brain tumors, venous sinus thrombosis, or hydrocephalus). MRI findings in IIH may include flattening of the posterior sclera, an empty sella turcica, and distension of the optic nerve sheaths.
- CT (Computed Tomography) may be performed as an alternative when MRI is contraindicated (e.g., due to pacemakers or severe claustrophobia), but has lower sensitivity and specificity for IIH.
2. Lumbar Puncture (Spinal Tap) This procedure involves the insertion of a needle into the lumbar spine to collect a sample of cerebrospinal fluid. It serves a dual purpose:
- Measurement of CSF opening pressure: the cornerstone of the diagnosis. A pressure greater than 25 cmH₂O in adults is considered elevated.
- CSF analysis to rule out infections, malignancy, and inflammatory conditions.
3. Ophthalmological Assessment A comprehensive eye examination should include:
- Fundoscopy (fundus examination) is performed to assess and grade the degree of optic disc edema.
- Visual acuity testing.
- Visual field testing (perimetry) is used to identify and monitor peripheral field defects.
4. Blood Tests
- A complete blood count (CBC) is useful to exclude anemia and lymphoproliferative disorders as contributing causes of papilledema
- Thyroid function tests, renal function, and metabolic panels may be indicated depending on clinical context
The diagnosis of IIH is confirmed when elevated intracranial pressure is documented in the absence of any identifiable secondary cause, with normal CSF composition.
Treatment
Management of IIH aims to reduce intracranial pressure, preserve vision, and alleviate symptoms, particularly headache. Treatment strategies range from lifestyle modification and pharmacotherapy to surgical intervention in refractory cases.
Lumbar Puncture as Symptomatic Relief
In some patients, a therapeutic lumbar puncture (with CSF drainage) can provide transient symptom relief and, in a small subset, may even lead to complete resolution. However, it is not a sustainable long-term treatment in the majority of cases.
Weight Loss
In overweight or obese patients, weight reduction of 5–10% of total body weight has been shown to be highly effective in inducing clinical remission of IIH. A structured, supervised weight loss program is therefore a cornerstone of management in eligible patients. Even modest weight loss can produce meaningful reductions in intracranial pressure.
Pharmacological Treatment
-
Carbonic anhydrase inhibitors (acetazolamide): the first-line pharmacological agent for IIH. Acetazolamide reduces CSF production by up to 50% and also acts as a mild diuretic. It is well-supported by clinical evidence and is generally well tolerated, though side effects include paresthesia (tingling), fatigue, and metabolic acidosis.
-
Topiramate: an anticonvulsant commonly used in migraine prophylaxis, has a weak carbonic anhydrase inhibitory effect. It may also facilitate weight loss, which makes it a useful adjunctive option. It is particularly considered in patients who cannot tolerate acetazolamide.
-
Diuretics (furosemide, chlorthalidone): loop and thiazide-like diuretics may be used as adjuncts or alternatives, though they are generally less effective than carbonic anhydrase inhibitors in reducing IIH-related symptoms.
-
Corticosteroids: while corticosteroids can rapidly lower intracranial pressure, their use must be approached with significant caution. They can cause weight gain, which is counterproductive in IIH, and may lead to a rebound increase in intracranial pressure when the dose is tapered. For these reasons, corticosteroids are generally reserved for patients with severe acute visual loss or those refractory to other medical treatments, and only for short-term use.
Surgical Treatment
Surgery is considered in patients who fail to respond adequately to medical management or who present with rapidly progressive or severe visual loss.
1. Optic Nerve Sheath Fenestration (ONSF) This procedure involves making small incisions in the meningeal sheaths (dura mater and arachnoid) surrounding the optic nerve just behind the eyeball. The slits allow CSF to drain away from the optic nerve, reducing local pressure and protecting it from ischemic damage. ONSF is primarily used to protect vision in patients with severe or refractory visual loss, and is less effective for headache relief.
2. CSF Diversion (Shunting) A surgically implanted shunt (either lumboperitoneal or ventriculoperitoneal) redirects excess CSF from the spinal or ventricular space into the peritoneal cavity, where it is safely reabsorbed. Shunting is particularly effective at reducing headache and overall intracranial pressure, though it carries risks of shunt malfunction, infection, and revision requirements. It is generally considered when headache is the predominant disabling symptom.
3. Venous Sinus Stenting In selected patients with evidence of transverse sinus stenosis (a relatively recently identified contributing mechanism), endovascular venous sinus stenting may be considered. Emerging evidence suggests this approach can lead to sustained reductions in intracranial pressure and symptom improvement.
Sources and Bibliography
- National Eye Institute (NIH): Idiopathic Intracranial Hypertension
- [Pseudotumor Cerebri: Jonathan Mondragon, Victoria Klovenski] StatPearls, NCBI](https://www.ncbi.nlm.nih.gov/books/NBK536924/)
- NHS: Intracranial Hypertension
- Wall M, et al. The idiopathic intracranial hypertension treatment trial: clinical profile at baseline. JAMA Neurology. 2014
- Mollan SP, et al. Idiopathic intracranial hypertension: consensus guidelines on management. Journal of Neurology, Neurosurgery & Psychiatry. 2018
- Friedman DI, Liu GT, Digre KB. Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children. Neurology. 2013
